Ivermectin, exactly.
CAHI is reporting there is a considerable issue in terms of the market share for industry, and this is decreasing competitiveness. Industry does not want to bring in these drugs, because if people are going to be able to get them more cheaply from across the border, then why should industry go through the regulatory process to do that?
One of Health Canada's concerns with personal use importation is if products are coming from China, India, or other countries where the standards are not identical or similar to the standards we have in Canada, we would have an issue. All you would need would be a safety issue because of an adulterated product coming across the border, and it would be huge.
So we've put together a task force. We did this in early 2007. Livestock producers are involved, CAHI is involved, and Agriculture Canada is involved as well. We brought them together and said we recognize the price differential issue for agriculture. We have to create an environment that's conducive to competitiveness for people to want to come in and file a submission, so that we would have these types of products. How do we restrict personal use importation? How do we make sure that what we are getting from across the border is not substandard or adulterated?
This is what we are working on right now. We are hoping that the task force will come up with some recommendations that will allow us to move forward.